Lv51
1120 积分 2025-06-23 加入
Overall Survival with Inavolisib in PIK3CA -Mutated Advanced Breast Cancer
15天前
已完结
Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3Kα
21天前
已完结
Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors
23天前
已完结
Differential Effects of Gefitinib and Cetuximab on Non–small-cell Lung Cancers Bearing Epidermal Growth Factor Receptor Mutations
1个月前
已完结
Exploring the structural activity relationship of the Osimertinib: A covalent inhibitor of double mutant EGFRL858R/T790M tyrosine kinase for the treatment of Non-Small Cell Lung Cancer (NSCLC)
1个月前
已完结
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status—A Real-World Analysis in Patients With Advanced NSCLC
2个月前
已关闭
Emerging landscape of KRAS inhibitors in cancer treatment
2个月前
已关闭
Cyclin-dependent kinase 4 and 6 inhibitors in breast cancer treatment
3个月前
已完结
Discovery of Atirmociclib (PF-07220060): A Potent and Selective CDK4 Inhibitor
3个月前
已完结
Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets
3个月前
已完结
皖公网安备34019202002308
